Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population

被引:78
作者
Abubaker, J. [1 ]
Bavi, P. [1 ]
Al-Harbi, S. [1 ]
Ibrahim, M. [1 ]
Siraj, A. K. [1 ]
Al-Sanea, N. [2 ]
Abduljabbar, A. [2 ]
Ashari, L. H. [2 ]
Alhomoud, S. [2 ]
Al-Dayel, F. [3 ]
Uddin, S. [1 ]
Al-Kuraya, K. S. [1 ]
机构
[1] King Faisal Specialist Hosp & Res Ctr, Dept Human Canc Genom Res, King Fahad Natl Ctr Childrens Canc & Res, Riyadh 11211, Saudi Arabia
[2] King Faisal Specialist Hosp & Res Ctr, Dept Colorectal Surg, Riyadh 11211, Saudi Arabia
[3] King Faisal Specialist Hosp & Res Ctr, Dept Pathol, Riyadh 11211, Saudi Arabia
关键词
PIK3CA; MSI; PTEN; colorectal cancer;
D O I
10.1038/sj.onc.1211013
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Activation of the phosphatidylinositol 3'-kinase (PI3K)/AKT pathway results in an increase in cell proliferation and survival. Somatic mutations within the PI3K catalytic subunit, PIK3CA are common cause of increasing PI3K activity and are believed to be oncogenic in many cancer types. Few reports addressed the association between PIK3CA mutations and tumor progression specifically in microsatellite instable (MSI) colorectal cancer (CRC). In the present study, we have evaluated PIK3CA mutational status in a series of 410 Middle Eastern CRC and 13 colon cell lines to study the prevalence of PIK3CA mutations in MSI cases, PTEN expression in CRC and possibility of therapeutic targeting of this set of patients. PIK3CA mutations were found in four of the cell lines tested and 51 colorectal carcinomas (12.2%). Three of these four mutated cell lines were MSI. PTEN was inactivated in 66.1% of the CRC. Furthermore, we observed a strong association between PIK3CA mutations and MSI status (P = 0.0046) while PTEN loss was more frequent in microsatellite stable (MSS) CRC (P = 0.043). A high prevalence of genetic alterations in PI3K/AKT pathway in Saudi cohort of CRC, predominance of PIK3CA mutations in the MSI subgroup and their possible involvement in development/progression of this subset of CRC are some of the significant findings of our study.
引用
收藏
页码:3539 / 3545
页数:7
相关论文
共 32 条
[1]   Analysis of the PI-3-kinase-PTEN-AKT pathway in human lymphoma and leukemia using a cell line microarray [J].
Abbott, RT ;
Tripp, S ;
Perkins, SL ;
Elenitoba-Johnson, KSJ ;
Lim, MS .
MODERN PATHOLOGY, 2003, 16 (06) :607-612
[2]   PIK3CA mutations are mutually exclusive with PTEN loss in diffuse large B-cell lymphoma [J].
Abubaker, J. ;
Bavi, P. P. ;
Al-Harbi, S. ;
Siraj, A. K. ;
Al-Dayel, F. ;
Uddin, S. ;
Al-Kuraya, K. .
LEUKEMIA, 2007, 21 (11) :2368-2370
[3]   Oncogenic PI3K deregulates transcription and translation [J].
Bader, AG ;
Kang, SY ;
Zhao, L ;
Vogt, PK .
NATURE REVIEWS CANCER, 2005, 5 (12) :921-929
[4]   Prevalence of fragile histidine triad expression in tumors from Saudi Arabia: A tissue microarray analysis [J].
Bavi, Prashant ;
Jehan, Zeenath ;
Atizado, Valerie ;
Al-Dossari, Hassan ;
Al-Dayel, Fouad ;
Tulbah, Asmah ;
Amr, Samir S. ;
Sheikh, Salwa S. ;
Ezzat, Adnan ;
El-Solh, Hassan ;
Uddin, Shahab ;
Al-Kuraya, Khawla .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2006, 15 (09) :1708-1718
[5]  
Boland CR, 1998, CANCER RES, V58, P5248
[6]   The Akt pathway in human breast cancer: a tissue-array-based analysis [J].
Bose, S ;
Chandran, S ;
Mirocha, JM ;
Bose, N .
MODERN PATHOLOGY, 2006, 19 (02) :238-245
[7]   Reduced expression of PTEN correlates with breast cancer progression [J].
Bose, S ;
Crane, A ;
Hibshoosh, H ;
Mansukhani, M ;
Sandweis, L ;
Parsons, R .
HUMAN PATHOLOGY, 2002, 33 (04) :405-409
[8]   Estimates of cancer incidence and mortality in Europe in 1995 [J].
Bray, F ;
Sankila, R ;
Ferlay, J ;
Parkin, DM .
EUROPEAN JOURNAL OF CANCER, 2002, 38 (01) :99-166
[9]   Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas [J].
Broderick, DK ;
Di, CH ;
Parrett, TJ ;
Samuels, YR ;
Cummins, JM ;
McLendon, RE ;
Fults, DW ;
Velculescu, VE ;
Bigner, DD ;
Yan, H .
CANCER RESEARCH, 2004, 64 (15) :5048-5050
[10]   Mutation of the PIK3CA gene in ovarian and breast cancer [J].
Campbell, IG ;
Russell, SE ;
Choong, DYH ;
Montgomery, KG ;
Ciavarella, ML ;
Hooi, CSF ;
Cristiano, BE ;
Pearson, RB ;
Phillips, WA .
CANCER RESEARCH, 2004, 64 (21) :7678-7681